Suppr超能文献

用于治疗掌腱膜挛缩症的Xiapex

▾Xiapex for Dupuytren's contracture.

出版信息

Drug Ther Bull. 2011 Dec;49(12):138-41. doi: 10.1136/dtb.2011.02.0072.

Abstract

Dupuytren's contracture is a benign, progressive disabling condition of the hands. Traditionally, surgery (e.g. fasciotomy, fasciectomy, joint fusion and amputation) has been the only effective treatment but it is not an option for every patient. A potential alternative intervention is a formulation of collagenase Clostridium histolyticum (▾Xiapex--Pfizer Limited), which has been licensed for injection directly into the affected joint as treatment for adults with Dupuytren's contracture.5 Here we review the evidence for collagenase C. histolyticum and discuss its place in the management of this condition.

摘要

杜普伊特伦挛缩症是一种手部的良性、进行性致残病症。传统上,手术(如筋膜切开术、筋膜切除术、关节融合术和截肢术)一直是唯一有效的治疗方法,但并非对每个患者都是可行选择。一种潜在的替代干预措施是溶组织梭状芽孢杆菌胶原酶制剂(▾Xiapex——辉瑞有限公司),该制剂已获许可直接注射到受影响关节,用于治疗患有杜普伊特伦挛缩症的成人。5在此,我们回顾了溶组织梭状芽孢杆菌胶原酶的相关证据,并讨论其在该病症治疗中的地位。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验